close
MENU
Business
3 mins to read

Kimer Med’s Series A to fund antiviral drug development

The Nelson-based biotech start-up aims to raise $14m, in a bid to transform the global fight against viral diseases with innovative antivirals.

Kimer Med has designed a platform for the rapid development of novel, broad-spectrum antivirals.

Liam Rātana Wed, 31 Jan 2024
Key points
  • What’s at stake: Kimer Med’s Series A funding round is crucial for advancing its groundbreaking work in developing broad-spectrum antiviral drugs, targeting an array of untreated viral diseases.
  • Background: Since its inception in 2020, Kimer has developed innovative platform for rapid antiviral drug development and a focus on combating diseases such as dengue fever.
  • Key players: Rick Kiessig, Phil Oliver, Callaghan Innovation, Massachusetts Institute of Technology, The University of Auckland.

Nelson-based biotech startup Kimer Med is running a Series A funding round, seeking to raise $14 million by August. The company has been developing a platform to develop broard-spectrum antiviral drugs, which could be a game-changer in the fight against viral diseases.

The Series A round follows a

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

NZ$399.00 / yearly

Offer ends July 31st

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Liam Rātana Wed, 31 Jan 2024
Contact the Writer: liam@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Key points
  • What’s at stake: Kimer Med’s Series A funding round is crucial for advancing its groundbreaking work in developing broad-spectrum antiviral drugs, targeting an array of untreated viral diseases.
  • Background: Since its inception in 2020, Kimer has developed innovative platform for rapid antiviral drug development and a focus on combating diseases such as dengue fever.
  • Key players: Rick Kiessig, Phil Oliver, Callaghan Innovation, Massachusetts Institute of Technology, The University of Auckland.
Kimer Med’s Series A to fund antiviral drug development
Business,
102491
true